Advertisement

Estimated Time to Maximum Medical Improvement of Intra-articular Injections in the Treatment of Knee Osteoarthritis—A Systematic Review

      Purpose

      The purpose of the current study is to perform a systematic review of the literature and evaluate maximum medical improvement and minimal clinically important difference (MCID) of different injectables in the treatment of symptomatic knee osteoarthritis.

      Methods

      A systematic review was performed to evaluate maximum medical improvement and MCID in patients undergoing injections of different modalities for knee osteoarthritis. Demographic factors of the patients being reviewed were analyzed, with patient-reported outcomes as reported by visual analog scale (VAS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) being used to evaluate the clinical trajectory of patients receiving intra-articular injections.

      Results

      Overall, 79 (level of evidence I: 79) studies met inclusion criteria, with 8761 patients. Corticosteroid (CS) injections, middle molecular weight hyaluronic acid (MMW-HA), and leukocyte-rich platelet rich plasma (LR-PRP) injections reached their maximum pain control at 4 to 6 weeks after injection, as measured by VAS. The lowest VAS scores were reached for low molecular weight hyaluronic acid (LMW-HA), high molecular weight hyaluronic acid (HMW-HA), and leukocyte-poor platelet rich plasma (LP-PRP) by 3 months after injection. Similarly, the WOMAC scores were lowest at 4 to 6 weeks after CS and MMW-HA injections, and at 3 months after HMW-HA and LP-PRP injections. LR-PRP demonstrated the most prolonged pain relief relative to the other injection types, with the lowest VAS score of all groups measured at final follow-up. LP-PRP showed the lowest WOMAC scores at final follow-up, one year post-injection.

      Conclusion

      PRP injections provide continued pain relief at up to 1 year after injection. Corticosteroids and hyaluronic acid have good efficacy and are suitable for many patients but lack this longevity.

      Level of Evidence

      Level I, a systematic review of Level I studies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Deshpande B.R.
        • Katz J.N.
        • Solomon D.H.
        • et al.
        Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity.
        Arthritis Care Res (Hoboken). 2016; 68: 1743-1750
        • Nelson A.E.
        Osteoarthritis year in review 2017: clinical.
        Osteoarthritis and cartilage. 2018; 26: 319-325
        • Bedenbaugh A.V.
        • Bonafede M.
        • Marchlewicz E.H.
        • Lee V.
        • Tambiah J.
        Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls.
        Clinicoecon Outcomes Res. 2021; 13: 421-435
        • Tan J.
        • Chen H.
        • Zhao L.
        • Huang W.
        Platelet-Rich Plasma Versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: A Meta-analysis of 26 Randomized Controlled Trials.
        Arthroscopy. 2021; 37: 309-325
        • Bannuru R.R.
        • Schmid C.H.
        • Kent D.M.
        • Vaysbrot E.E.
        • Wong J.B.
        • McAlindon T.E.
        Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
        Ann Intern Med. 2015; 162: 46-54
        • Huang Y.
        • Liu X.
        • Xu X.
        • Liu J.
        Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis : A prospective randomized controlled study.
        Orthopade. 2019; 48: 239-247
        • Kompel A.J.
        • Roemer F.W.
        • Murakami A.M.
        • Diaz L.E.
        • Crema M.D.
        • Guermazi A.
        Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought?.
        Radiology. 2019; 293: 656-663
        • Ricci M.
        • Micheloni G.M.
        • Berti M.
        • et al.
        Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis.
        Musculoskelet Surg. 2017; 101: 45-49
        • Yaftali N.A.
        • Weber K.
        Corticosteroids and Hyaluronic Acid Injections.
        Clin Sports Med. 2019; 38: 1-15
        • Strauss E.
        • Schachter A.
        • Frenkel S.
        • Rosen J.
        The efficacy of intra-articular hyaluronan injection after the microfracture technique for the treatment of articular cartilage lesions.
        Am J Sports Med. 2009; 37: 720-726
        • Strauss E.J.
        • Barker J.U.
        • Kercher J.S.
        • Cole B.J.
        • Mithoefer K.
        Augmentation Strategies following the Microfracture Technique for Repair of Focal Chondral Defects.
        Cartilage. 2010; 1: 145-152
        • Wang Y.
        • Hall S.
        • Hanna F.
        • et al.
        Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial.
        BMC Musculoskelet Disord. 2011; 12: 195
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6e1000097
        • Higgins J.P.T.
        • Altman D.G.
        • Gotzsche P.C.
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343 (d5928-d5928)
        • Tashjian R.Z.
        • Deloach J.
        • Porucznik C.A.
        • Powell A.P.
        Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease.
        Journal of Shoulder and Elbow Surgery. 2009; 18: 927-932
        • Clement N.D.
        • Bardgett M.
        • Weir D.
        • Holland J.
        • Gerrand C.
        • Deehan D.J.
        What is the Minimum Clinically Important Difference for the WOMAC Index After TKA?.
        Clin Orthop Relat Res. 2018; 476: 2005-2014
        • Nwachukwu B.U.
        • Chang B.
        • Fields K.
        • et al.
        Defining the "Substantial Clinical Benefit" After Arthroscopic Treatment of Femoroacetabular Impingement.
        Am J Sports Med. 2017; 45: 1297-1303
        • Martin R.L.
        • Kivlan B.R.
        • Christoforetti J.J.
        • et al.
        Minimal Clinically Important Difference and Substantial Clinical Benefit Values for the 12-Item International Hip Outcome Tool.
        Arthroscopy. 2019; 35: 411-416
        • Cvetanovich G.L.
        • Weber A.E.
        • Kuhns B.D.
        • et al.
        Clinically Meaningful Improvements After Hip Arthroscopy for Femoroacetabular Impingement in Adolescent and Young Adult Patients Regardless of Gender.
        J Pediatr Orthop. 2018; 38: 465-470
        • Zimmerer A.
        • Janz V.
        • Sobau C.
        • Wassilew G.I.
        • Miehlke W.
        Defining the Clinically Meaningful Outcomes for Arthroscopic Treatment of Femoroacetabular Impingement Syndrome at Minimum 10-Year Follow-up: The Timing of Surgery Is Crucial.
        Orthopaedic Journal of Sports Medicine. 2021; 9 (2325967120985140)
        • Cook C.E.
        Clinimetrics Corner: The Minimal Clinically Important Change Score (MCID): A Necessary Pretense.
        J Man Manip Ther. 2008; 16: E82-83
        • Cabarcas B.C.
        • Gowd A.K.
        • Liu J.N.
        • et al.
        Establishing maximum medical improvement following reverse total shoulder arthroplasty for rotator cuff deficiency.
        Journal of Shoulder and Elbow Surgery. 2018; 27: 1721-1731
        • Gregori D.
        • Giacovelli G.
        • Minto C.
        • et al.
        Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis.
        JAMA. 2018; 320: 2564-2579
        • Freire M.R.M.
        • da Silva P.M.C.
        • Azevedo A.R.
        • Silva D.S.
        • da Silva R.B.B.
        • Cardoso J.C.
        Comparative Effect between Infiltration of Platelet-rich Plasma and the Use of Corticosteroids in the Treatment of Knee Osteoarthritis: A Prospective and Randomized Clinical Trial.
        Rev Bras Ortop (Sao Paulo). 2020; 55: 551-556
        • Meheux C.J.
        • McCulloch P.C.
        • Lintner D.M.
        • Varner K.E.
        • Harris J.D.
        Efficacy of Intra-articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Systematic Review.
        Arthroscopy. 2016; 32: 495-505
        • Riboh J.C.
        • Saltzman B.M.
        • Yanke A.B.
        • Fortier L.
        • Cole B.J.
        Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis.
        Am J Sports Med. 2016; 44: 792-800
        • Jüni P.
        • Hari R.
        • Rutjes A.W.S.
        • et al.
        Intra-articular corticosteroid for knee osteoarthritis.
        Cochrane Database of Systematic Reviews. 2015;
        • Matzkin E.G.
        • Curry E.J.
        • Kong Q.
        • Rogers M.J.
        • Henry M.
        • Smith E.L.
        Efficacy and Treatment Response of Intra-articular Corticosteroid Injections in Patients With Symptomatic Knee Osteoarthritis.
        JAAOS - Journal of the American Academy of Orthopaedic Surgeons. 2017; 25: 703-714
        • Bedard N.A.
        • DeMik D.E.
        • Glass N.A.
        • Burnett R.A.
        • Bozic K.J.
        • Callaghan J.J.
        Impact of Clinical Practice Guidelines on Use of Intra-Articular Hyaluronic Acid and Corticosteroid Injections for Knee Osteoarthritis.
        JBJS. 2018; 100: 827-834
        • Cooper C.
        • Rannou F.
        • Richette P.
        • et al.
        Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.
        Arthritis Care Res (Hoboken). 2017; 69: 1287-1296
        • Rayahin J.E.
        • Buhrman J.S.
        • Zhang Y.
        • Koh T.J.
        • Gemeinhart R.A.
        High and low molecular weight hyaluronic acid differentially influence macrophage activation.
        ACS Biomater Sci Eng. 2015; 1: 481-493
        • Mohebbi R.
        • Rezasoltani Z.
        • Mir M.
        • Mohebbi M.
        • Vatandoost S.
        • Esmaily H.
        High- Versus Low-Molecular-Weight Hyaluronic Acid for the Treatment of Rotator Cuff Tendinopathy: A Triple-Blind Randomized Comparative Trial.
        Ann Pharmacother. 2021; (1060028021994297)
        • Shen L.
        • Yuan T.
        • Chen S.
        • Xie X.
        • Zhang C.
        The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials.
        J Orthop Surg Res. 2017; 12: 16
        • Wu P.I.
        • Diaz R.
        • Borg-Stein J.
        Platelet-Rich Plasma.
        Phys Med Rehabil Clin N Am. 2016; 27: 825-853
        • Dai W.
        • Leng X.
        • Wang J.
        • et al.
        Intra-Articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
        Arthroscopy. 2021; 37: 340-358